Medicine

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

M. Wobser, Andreas Rosenwald, F. Eisele, K. Maurus, Max S. Topp, J. Duell

2026.5.22LEUKEMIA & LYMPHOMA

DOI: 10.1080/10428194.2026.2672106

Resumen

El resumen no está disponible.

Formato de cita

WOBSER, M., et al. Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large b-cell lymphoma. LEUKEMIA & LYMPHOMA, 2026: 1–4.